Metrics as of 10/14/2026, 10:47 PM (Berlin time), refresh in progress.
Medacta Group Stock
Medacta Group S.A.
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- Switzerland
- CEO
- Francesco Siccardi
- Employees
- 2,273
- Market cap
- CHF2.3 B
- IPO
- 03/04/2019
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating within the Healthcare sector as part of the Medical - Specialties industry, the company delivers specialized solutions across Europe,…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Medacta Group stock: price history
1D
+0.4%
1W
+0.2%
1M
-0.9%
6M
-28.6%
YTD
-26.9%
1Y
-21.6%
2Y
-5.6%
5Y
-26.6%
10Y
–
Next earnings date
Next earnings date
12/03/2027 (in 146 days)
Volatility around earnings
~15% weaker price swings than usual
Ask the agents about Medacta Group
Medacta Group stock metrics
P/E
31.57
P/B
5.05
EV/EBITDA
14.27
RETURN ON EQUITY
8.6%
NET MARGIN
11.4%
DEBT/EQUITY
0.66
DIVIDEND YIELD
1.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
30.1%
FLOAT SHARES
5,998,503
AVG. DAILY VOLUME (30D)
35,054
Dividends
Comparable stocks
Frequently asked questions about Medacta Group stock
What does Medacta Group do?
Medacta Group S.A. is a company in the Healthcare sector, Medical - Specialties industry, headquartered in Switzerland.
The CEO is Francesco Siccardi, the company employs around 2,273 people.
The IPO was on 03/04/2019; the stock trades on SIX under the ticker MOVE.SW.
When does Medacta Group report next?
The next earnings date is 12/03/2027.
Around past earnings, price swings were roughly -15% stronger than usual.
Does Medacta Group pay a dividend?
Yes. The last dividend was CHF 1.10 per share, ex-date 07/05/2026, paid on 11/05/2026.
The dividend yield is 1.0% (as of 30/06/2026).
Which stocks are comparable to Medacta Group?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Roche Holding, BeOne Medicines and Sandoz Group.
How can I get Medacta Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Medacta Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.